Drug Search Results
More Filters [+]

ABBV-668

Alternative Names: ABBV-668, ABBV 668, ABBV668
Latest Update: 2024-10-08
Latest Update Note: Clinical Trial Update

Product Description

ABBV-668 is an inhibitor of receptor-interacting protein kinase 1 (RIPK1) being investigated for the treatment of several immune-mediated diseases. (Sourced from: https://www.abbvie.com/our-science/pipeline/abbv-668.html)

Mechanisms of Action: RIPK1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ABBV-668

Countries in Clinic: Belgium, France, Poland, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Colitis, Ulcerative

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

M21-446

P2

Unknown Status

Colitis, Ulcerative

2025-04-01

M21-446

P2

Active, not recruiting

Colitis, Ulcerative

2024-12-25

M25-176

P1

Completed

Healthy Volunteers

2024-09-20

Recent News Events

Date

Type

Title